Hodgkin Lymphoma-Pipeline Review, H1 2015

Hodgkin Lymphoma-Pipeline Review, H1 2015

  • Products Id :- GMDHC6031IDB
  • |
  • Pages: 244
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Hodgkin Lymphoma-Pipeline Review, H1 2015


Global Markets Direct's, 'Hodgkin Lymphoma-Pipeline Review, H1 2015', provides an overview of the Hodgkin Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hodgkin Lymphoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Hodgkin Lymphoma Overview 11

Therapeutics Development 12

Pipeline Products for Hodgkin Lymphoma-Overview 12

Pipeline Products for Hodgkin Lymphoma-Comparative Analysis 13

Hodgkin Lymphoma-Therapeutics under Development by Companies 14

Hodgkin Lymphoma-Therapeutics under Investigation by Universities/Institutes 17

Hodgkin Lymphoma-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Hodgkin Lymphoma-Products under Development by Companies 21

Hodgkin Lymphoma-Products under Investigation by Universities/Institutes 24

Hodgkin Lymphoma-Companies Involved in Therapeutics Development 25

4SC AG 25

Acetylon Pharmaceuticals, Inc. 26

Actinium Pharmaceuticals, Inc. 27

Affimed Therapeutics AG 28

Aptose Biosciences Inc. 29

AVEO Pharmaceuticals, Inc. 30

Bristol-Myers Squibb Company 31

Constellation Pharmaceuticals, Inc. 32

Dynavax Technologies Corporation 33

Gamida Cell Ltd. 34

Incyte Corporation 35

Johnson & Johnson 36

MABLife S.A.S 37

Merck & Co., Inc. 38

Novartis AG 39

Ono Pharmaceutical Co., Ltd. 40

Pharmacyclics, Inc. 41

Philogen S.p.A. 42

Seattle Genetics, Inc. 43

Sigma-Tau S.p.A. 44

Spectrum Pharmaceuticals, Inc. 45

Stemline Therapeutics, Inc. 46

Syndax Pharmaceuticals, Inc. 47

Takeda Oncology 48

Tekmira Pharmaceuticals Corp. 49

TG Therapeutics, Inc. 50

Hodgkin Lymphoma-Therapeutics Assessment 51

Assessment by Monotherapy Products 51

Assessment by Target 52

Assessment by Mechanism of Action 55

Assessment by Route of Administration 58

Assessment by Molecule Type 60

Drug Profiles 62

abexinostat hydrochloride-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

AFM-13-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

APTO-253-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

BMS-986016-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

brentuximab vedotin-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Cell Therapy 2 for Oncology and Infectious Disease-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Cell Therapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Cell Therapy to Target CD30 for Relapsed and Refractory Lymphomas-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

Cell Therapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Cell Therapy to Target LMP-1 and LMP-2 for Oncology-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Cell Therapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

CPI-0610-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Dendritic Cell Therapy for Oncology-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

entinostat-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Ferritarg-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

ficlatuzumab-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Iomab-B-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

ixazomib citrate-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

JNJ-40346527-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

LMP-400-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

LMP-776-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

MDX-1401-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

MK-2206-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

Monoclonal Antibody Conjugate to Target CD45 for Oncology-Drug Profile 105

Product Description 105

Mechanism of Action 105

R&D Progress 105

NiCord-Drug Profile 106

Product Description 106

Mechanism of Action 106

R&D Progress 106

nivolumab (recombinant)-Drug Profile 107

Product Description 107

Mechanism of Action 107

R&D Progress 107

NSC-678515-Drug Profile 112

Product Description 112

Mechanism of Action 112

R&D Progress 112

panobinostat-Drug Profile 113

Product Description 113

Mechanism of Action 113

R&D Progress 113

pembrolizumab-Drug Profile 119

Product Description 119

Mechanism of Action 119

R&D Progress 119

pevonedistat hydrochloride-Drug Profile 123

Product Description 123

Mechanism of Action 123

R&D Progress 123

procarbazine hydrochloride-Drug Profile 125

Product Description 125

Mechanism of Action 125

R&D Progress 125

radretumab-Drug Profile 126

Product Description 126

Mechanism of Action 126

R&D Progress 126

resminostat-Drug Profile 128

Product Description 128

Mechanism of Action 128

R&D Progress 128

ricolinostat-Drug Profile 132

Product Description 132

Mechanism of Action 132

R&D Progress 132

RP-5264-Drug Profile 134

Product Description 134

Mechanism of Action 134

R&D Progress 134

ruxolitinib phosphate-Drug Profile 136

Product Description 136

Mechanism of Action 136

R&D Progress 136

SD-101-Drug Profile 141

Product Description 141

Mechanism of Action 141

R&D Progress 141

SL-101-Drug Profile 143

Product Description 143

Mechanism of Action 143

R&D Progress 143

SL-501-Drug Profile 144

Product Description 144

Mechanism of Action 144

R&D Progress 144

StemEx-Drug Profile 145

Product Description 145

Mechanism of Action 145

R&D Progress 145

TKM-PLK1-Drug Profile 146

Product Description 146

Mechanism of Action 146

R&D Progress 146

vinorelbine tartrate liposomal-Drug Profile 148

Product Description 148

Mechanism of Action 148

R&D Progress 148

Hodgkin Lymphoma-Recent Pipeline Updates 150

Hodgkin Lymphoma-Dormant Projects 223

Hodgkin Lymphoma-Discontinued Products 226

Hodgkin Lymphoma-Product Development Milestones 227

Featured News & Press Releases 227

Dec 09, 2014: Affimed Presents Final Data for AFM13 Phase 1 Trial at ASH 227

Dec 08, 2014: Seattle Genetics Highlights Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting 227

Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting 231

Dec 06, 2014: Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma 233

Dec 06, 2014: Data Investigating KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting 235

Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014 236

Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting 238

Oct 13, 2014: Takedas Adcetri (brentuximab vedotin) is the first ultra-orphan medicine to be accepted by the SMC via the new assessment process 239

Sep 29, 2014: Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS (Brentuximab Vedotin) for Consolidation in Post-Transplant Hodgkin Lymphoma 240

Sep 26, 2014: Seattle Genetics to Host Conference Call and Webcast on September 29, 2014 Regarding Top-line Data from ADCETRIS (brentuximab vedotin) Phase 3 AETHERA Clinical Trial 242

Appendix 243

Methodology 243

Coverage 243

Secondary Research 243

Primary Research 243

Expert Panel Validation 243

Contact Us 244

Disclaimer 244

List of Tables

Number of Products under Development for Hodgkin Lymphoma, H1 2015 12

Number of Products under Development for Hodgkin Lymphoma-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Late Stage Development, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Development, H1 2015 20

Products under Development by Companies, H1 2015 21

Products under Development by Companies, H1 2015 (Contd..1) 22

Products under Development by Companies, H1 2015 (Contd..2) 23

Products under Investigation by Universities/Institutes, H1 2015 24

Hodgkin Lymphoma-Pipeline by 4SC AG, H1 2015 25

Hodgkin Lymphoma-Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015 26

Hodgkin Lymphoma-Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 27

Hodgkin Lymphoma-Pipeline by Affimed Therapeutics AG, H1 2015 28

Hodgkin Lymphoma-Pipeline by Aptose Biosciences Inc., H1 2015 29

Hodgkin Lymphoma-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 30

Hodgkin Lymphoma-Pipeline by Bristol-Myers Squibb Company, H1 2015 31

Hodgkin Lymphoma-Pipeline by Constellation Pharmaceuticals, Inc., H1 2015 32

Hodgkin Lymphoma-Pipeline by Dynavax Technologies Corporation, H1 2015 33

Hodgkin Lymphoma-Pipeline by Gamida Cell Ltd., H1 2015 34

Hodgkin Lymphoma-Pipeline by Incyte Corporation, H1 2015 35

Hodgkin Lymphoma-Pipeline by Johnson & Johnson, H1 2015 36

Hodgkin Lymphoma-Pipeline by MABLife S.A.S, H1 2015 37

Hodgkin Lymphoma-Pipeline by Merck & Co., Inc., H1 2015 38

Hodgkin Lymphoma-Pipeline by Novartis AG, H1 2015 39

Hodgkin Lymphoma-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 40

Hodgkin Lymphoma-Pipeline by Pharmacyclics, Inc., H1 2015 41

Hodgkin Lymphoma-Pipeline by Philogen S.p.A., H1 2015 42

Hodgkin Lymphoma-Pipeline by Seattle Genetics, Inc., H1 2015 43

Hodgkin Lymphoma-Pipeline by Sigma-Tau S.p.A., H1 2015 44

Hodgkin Lymphoma-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 45

Hodgkin Lymphoma-Pipeline by Stemline Therapeutics, Inc., H1 2015 46

Hodgkin Lymphoma-Pipeline by Syndax Pharmaceuticals, Inc., H1 2015 47

Hodgkin Lymphoma-Pipeline by Takeda Oncology, H1 2015 48

Hodgkin Lymphoma-Pipeline by Tekmira Pharmaceuticals Corp., H1 2015 49

Hodgkin Lymphoma-Pipeline by TG Therapeutics, Inc., H1 2015 50

Assessment by Monotherapy Products, H1 2015 51

Number of Products by Stage and Target, H1 2015 53

Number of Products by Stage and Mechanism of Action, H1 2015 56

Number of Products by Stage and Route of Administration, H1 2015 59

Number of Products by Stage and Molecule Type, H1 2015 61

Hodgkin Lymphoma Therapeutics-Recent Pipeline Updates, H1 2015 150

Hodgkin Lymphoma-Dormant Projects, H1 2015 223

Hodgkin Lymphoma-Dormant Projects (Contd..1), H1 2015 224

Hodgkin Lymphoma-Dormant Projects (Contd..2), H1 2015 225

Hodgkin Lymphoma-Discontinued Products, H1 2015 226

List of Figures

Number of Products under Development for Hodgkin Lymphoma, H1 2015 12

Number of Products under Development for Hodgkin Lymphoma-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Late Stage Development, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Products, H1 2015 20

Assessment by Monotherapy Products, H1 2015 51

Number of Products by Top 10 Targets, H1 2015 52

Number of Products by Stage and Top 10 Targets, H1 2015 52

Number of Products by Top 10 Mechanism of Actions, H1 2015 55

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 55

Number of Products by Top 10 Routes of Administration, H1 2015 58

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 58

Number of Products by Top 10 Molecule Types, H1 2015 60

Number of Products by Stage and Top 10 Molecule Types, H1 2015 61

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com


Acetylon Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

Affimed Therapeutics AG

Aptose Biosciences Inc.

AVEO Pharmaceuticals, Inc.

Bristol-Myers Squibb Company

Constellation Pharmaceuticals, Inc.

Dynavax Technologies Corporation

Gamida Cell Ltd.

Incyte Corporation

Johnson & Johnson


Merck & Co., Inc.

Novartis AG

Ono Pharmaceutical Co., Ltd.

Pharmacyclics, Inc.

Philogen S.p.A.

Seattle Genetics, Inc.

Sigma-Tau S.p.A.

Spectrum Pharmaceuticals, Inc.

Stemline Therapeutics, Inc.

Syndax Pharmaceuticals, Inc.

Takeda Oncology

Tekmira Pharmaceuticals Corp.

TG Therapeutics, Inc.

Hodgkin Lymphoma Therapeutic Products under Development, Key Players in Hodgkin Lymphoma Therapeutics, Hodgkin Lymphoma Pipeline Overview, Hodgkin Lymphoma Pipeline, Hodgkin Lymphoma Pipeline Assessment

select a license
Single User License
USD 2000 INR 146960
Site License
USD 4000 INR 293920
Corporate User License
USD 6000 INR 440880



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com